Group 1 - Shanghai is focusing on creating a long-term, stable, transparent, and predictable development environment to provide new opportunities for global enterprises [2] - The "14th Five-Year Plan" emphasizes high-level opening up and prioritizes technological innovation, aiming for high-quality development in Shanghai [2] - The biopharmaceutical industry is one of the three key leading industries in Shanghai, with a call for increased innovation and collaboration in drug development from global leaders like Boehringer Ingelheim [2] Group 2 - Zeiss, a leading manufacturer of optical and optoelectronic equipment, is encouraged to enhance its regional headquarters functions and increase R&D and manufacturing presence in Shanghai [2] - Both companies expressed commitment to deepening innovation and collaboration in the Chinese market, with Boehringer Ingelheim focusing on human pharmaceuticals and animal health [4] - Zeiss highlighted the importance of Shanghai's business environment and strategic development plans, reinforcing its investment confidence in the region [4]

这一年，中国科技成果丰硕，创新生态日趋完善。华为持续"压强式"研发，在算力、鸿蒙生态、通信网 络、终端市场等七大领域实现硬核突破；寒武纪10年攻关实现AI芯片国产化突破；商业航天竞速，6家 企业集体冲击IPO…… 这一年，科技创新与产业融合加速。阿里巴巴3800亿元投向未来，通义千问串起阿里AI生态；全球代 工巨头工业富联（601138）蜕变为万亿算力巨头；恒瑞医药（600276）从仿制转向创新，I类新药频频 借船出海…… 科技突破、产业竞争力的提升，来自对创新的投入。根据国家统计局披露的数据，2025年，中国企业研 发经费达3.93万亿元，稳居世界第二，研发投入强度2.8%，首次超越OECD国家平均水平。 AI时代奔涌而来，创新浪潮澎湃。 2025年，是中国科技在风浪中磨砺韧性的一年，也是于变局中开创新局的关键一年。 传统产业融合焕发新动能 新兴产业不断突围前行，传统产业融合新兴科技，释放出充满活力的新质生产力。 在AI浪潮之下，"代工之王"工业富联实现关键突围，深度绑定全球科技巨头苹果、英伟达，实现了 向"全球AI算力基建供应商"的蜕变。根据公开信息，工业富联AI服务器全球代工市占率超35%，800G 高 ...

Core Viewpoint - The simplified tax policy for biological products, including vaccines, will be canceled starting this year, with a transition to general tax calculation methods by 2026, impacting the tax burden on related enterprises [1][2][3]. Group 1: Tax Policy Changes - The simplified tax rate of 3% for biological products will no longer apply from this year, as stated in the recent announcement by the Ministry of Finance and the State Administration of Taxation [1][2]. - From January 1, 2026, general taxpayers selling biological products will need to determine applicable tax rates based on specific product types, moving away from the simplified tax method [2][3]. - The announcement specifies that the simplified tax policy for biological products will cease, aligning with the broader changes in the VAT law [1][3]. Group 2: Impact on Enterprises - The cancellation of the simplified tax policy may lead to increased tax burdens for some biological product enterprises, particularly those with insufficient input tax credits [5]. - Companies with well-established supply chains and sufficient input tax deductions may see a balanced or reduced tax burden under the general tax method [5]. - Enterprises are advised to reassess their supplier and customer relationships and adjust pricing strategies to adapt to the new tax policy [5][6]. Group 3: Retained Tax Benefits - Certain biological products, such as anti-cancer drugs and rare disease medications, will continue to benefit from the 3% simplified tax rate until December 31, 2027 [6]. - The announcement outlines four specific policies that will remain effective for these products, ensuring continued support for critical healthcare needs [6].

Group 1: Product Development and Clinical Trials - The innovative drug Lakanqita Monoclonal Antibody targets IL-17A/F and is the first of its kind in China, with core indications for moderate to severe psoriasis and ankylosing spondylitis [2][3] - The Phase III clinical trial for psoriasis showed a PASI100 response rate of 49.5% at week 12, significantly higher than the 40.2% response rate of Secukinumab, achieving statistical superiority [2][3] - The ankylosing spondylitis indication is expected to be submitted for approval in Q2 2026, with the psoriasis indication anticipated to receive approval by the end of this year [2][3] Group 2: Market Potential and Commercial Strategy - The market potential for autoimmune skin diseases in China is substantial, with expectations for growth as the accessibility of biological agents increases [3] - The company has initiated overseas collaboration discussions and signed confidentiality agreements with potential partners to explore new indications and leverage international clinical experience [3] - A comprehensive commercial strategy is in place, including brand image development and participation in dermatology conferences to promote clinical research results [3] Group 3: Vaccine Development - The company is focusing on both therapeutic and preventive biological products, leveraging its established recombinant protein vaccine platform developed during the COVID-19 pandemic [4][5] - The quadrivalent recombinant protein influenza vaccine, the first of its kind with an adjuvant, aims to enhance immune protection, particularly for the elderly and patients with chronic diseases [5] - The influenza vaccine is expected to enter Phase II clinical trials in the first half of 2026, following successful Phase I trials [5] Group 4: Fertility Treatment Products - The recombinant human follicle-stimulating hormone injection is a key product in the assisted reproduction sector, designed for ease of use with a reusable injection pen [6] - This product is projected to be approved for market release in 2026, with growing demand anticipated in the domestic assisted reproduction market [6] Group 5: Research and Development Principles - The company has established clear and rigorous product development principles focusing on disease area specialization, technological innovation, scientific research, and commercial viability [7][8] - Emphasis is placed on differentiated innovation to avoid homogenization and build unique market advantages [8] Group 6: AI Integration in Operations - The company is implementing AI technology across its entire business chain, significantly enhancing efficiency in research and development [8] - In the development of the quadrivalent recombinant protein influenza vaccine, AI tools reduced the optimization time for processes by over 50%, achieving a fourfold increase in antigen expression and a 98% reduction in host protein impurities [8]

（文章来源：证券日报） 证券日报网讯 1月30日，亚虹医药发布公告称，公司预计2025年度实现营业收入约24，248.13万元到 29，097.76万元，同比增长20.30%到44.36%；归属于母公司所有者的净利润为-37，766.54万元到-45， 319.85万元。 ...

Core Insights - Company has entered into a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, marking the seventh partnership between the two entities [1] - The collaboration aims to leverage complementary strengths to accelerate the global development of innovative drugs, with the company leading projects from drug discovery to clinical concept validation in China [1] - Eli Lilly will obtain exclusive global development and commercialization rights outside Greater China, while the company retains all rights within Greater China [1] Financial Terms - The agreement includes an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future milestones [2] - The company is entitled to a tiered sales share from net sales of each product outside Greater China [2] Collaboration Model - This partnership breaks traditional licensing models, creating a seamless end-to-end innovation ecosystem that integrates the company's flexible drug discovery and early development capabilities with Eli Lilly's extensive global presence [2] - The collaboration underscores the company's core R&D capabilities and aims to expedite the translation of scientific discoveries into globally impactful medical solutions [2]

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, marking the seventh partnership between the two companies [1][2] Group 1: Partnership Details - The collaboration involves Innovent Biologics and its subsidiaries, including Fortvita Biologics, and Eli Lilly, focusing on the global development of innovative drugs [1] - Innovent will lead the projects from drug discovery to clinical concept verification in China, while Eli Lilly will have exclusive development and commercialization rights outside Greater China [1] Group 2: Financial Aspects - Innovent will receive an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future achievements [2] - The company will also earn a tiered sales share from net sales of each product outside Greater China [2] Group 3: Innovation Ecosystem - This partnership breaks traditional licensing models, creating a seamless end-to-end innovation ecosystem that integrates Innovent's drug discovery and early development capabilities with Eli Lilly's extensive global presence [2] - The collaboration reinforces Innovent's core R&D capabilities and aims to accelerate the translation of scientific discoveries into impactful medical solutions for global patients [2]

Core Viewpoint - The company has entered into a strategic collaboration with Eli Lilly to advance the global development of innovative drugs in the oncology and immunology fields, which includes significant financial incentives and revenue-sharing opportunities [1] Group 1: Strategic Collaboration - The company, along with its subsidiaries, has formed a partnership with Eli Lilly to enhance drug development in oncology and immunology [1] - The agreement includes an upfront payment of $350 million to the company [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] Group 2: Revenue Sharing - The company will have the right to receive a tiered sales share from net sales outside of Greater China for each product developed under this collaboration [1]

Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, marking their seventh partnership and enhancing their long-term relationship [1][2]. Group 1: Strategic Collaboration - Innovent Biologics, along with its subsidiaries, has entered into a strategic collaboration with Eli Lilly to promote global R&D of innovative drugs in oncology and immunology [1]. - The agreement allows Innovent to leverage its mature antibody technology platform and efficient clinical capabilities to lead projects from drug discovery to clinical concept validation in China [1][2]. - Eli Lilly will obtain exclusive global development and commercialization rights for the projects outside Greater China, while Innovent retains all rights within Greater China [1]. Group 2: Financial Terms - Innovent will receive an upfront payment of $350 million, with the potential to earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [2]. - The company will also be entitled to a tiered sales share based on net sales of each product outside Greater China [2]. Group 3: Innovation Ecosystem - This collaboration breaks traditional licensing models, creating a seamless end-to-end innovation ecosystem that integrates Innovent's flexible drug discovery and early development capabilities with Eli Lilly's extensive global presence [2]. - The partnership underscores Innovent's core R&D strength and aims to accelerate the translation of scientific discoveries into impactful medical solutions for global patients [2].

2月6日，复宏汉霖召开了投资者交流会。会上，朱俊表示，复宏汉霖从三年前就开始对日本市场进行战 略性布局并组建了当地团队，原拟自行进行汉斯状在日本的上市及商业化工作，之所以放弃原计划，转 而与卫材进行"出海"合作，主要是因为卫材给出的报价"非常有诚意"。 另据复宏汉霖官方微信号消息，目前，汉斯状正在日本开发的适应症有：广泛期小细胞肺癌、非微卫星 高度不稳定型转移性结直肠癌，并计划开展一项针对胃癌围手术期治疗的临床研究。 关于这些适应症的开发进度，复宏汉霖首席商务发展官、高级副总裁曹平在投资者交流会上对记者表 示，针对广泛期小细胞肺癌，复宏汉霖正在日本开展二期桥接临床试验，预计可在卫材的2026财年期间 在日本递交上市申请；针对非微卫星高度不稳定型转移性结直肠癌，汉斯状正在进行国际多中心三期临 床试验。"根据现有的开发进度时间表，预计到2028年，汉斯状应用于广泛期小细胞肺癌、非微卫星高 度不稳定型转移性结直肠癌治疗的适应症有望在日本获批，胃癌围手术期治疗的适应症则有望于2029年 获批。"曹平透露。 这也就是说，最早于2028年，汉斯状可在日本产生销售，复宏汉霖可获得销售提成。 日前，上海复宏汉霖生物技术股份有 ...